

AN INVESTIGATION CERVICAL CANCER, HUMAN PAPILLOMAVIRUS (HPV) INFECTION AND STEROID CONTRACEPTION

Manivasan Moodley

Submitted in partial fulfilment of the requirement for the degree of
Philosophiae Doctor in Obstetrics Gynaecology

University of Pretoria
Pretoria
South Africa

Supervisor: Professor BG Lindeque



UNIVERSITEIT VAN PRETORIA
UNIVERSITY OF PRETORIA
YUNIBESITHI YA PRETORIA



**Submitted in partial fulfilment of the requirements for the
degree of PhD in the department of Obstetrics and
Gynaecology, University of Pretoria, South Africa**

ABSTRACT

PROJECT ONE

Introduction

HPV is detected in about 99.7% of cervical cancers. However, the HPV type distribution in South African women is unknown.

Objectives

To determine HPV-type distribution among women with cervical dysplasia in relation to oral contraceptive usage.

Methods

Prospective cross-sectional study of four groups of patients according to oral contraceptive usage: non-users, users of less than five years duration, users of between five years and ten years and users of more than ten years duration. Swabs of the cervix were analysed for HPV DNA using polymerase chain reaction method.

Results

A total of 124 women were recruited for the study. There were 75 HIV-infected patients (seroprevalence 61%). Of the 102(82%) HPV-positive patients, 79 patients had high-risk HPV DNA (78%). In terms of the four oral contraceptive groups, high-risk HPV DNA was detected in 70% (n=21), 79% (n=22), 90% (n=21) and 71% (n=15) of patients, respectively. The odds of having HPV DNA was six times higher for the combination of contraceptive users of less than 5 years duration/non-users (OR 5.9, 95% CI: 1.87 - 18.77).

There was no change when adjustment was made for age (OR 6.1, 95% CI: 1.9 - 19.4). HPV DNA types 16 and or 18 was present in a total of 21 patients (49%) (non-contraceptive users and users < 5years duration) versus 15 patients (42%) who used oral contraceptives of more than 5 years duration (p=0.524). HPV type 16 was the commonest HPV type detected (20.2%) and HPV type 58 was the next commonest high-risk HPV type (16.1%). HPV types 58 and 33 was detected in a much greater percentage of our population and HPV 16 in a much smaller percentage of our population compared with a non-South African population.

Conclusion

The findings of this study demonstrate an interesting distribution of HPV types in a South African population.

PROJECT TWO

Introduction

Various risk factors have been implicated in the causation of cervical cancer including human papillomavirus (HPV), the early genes (*E6* and *E7*) of which encode the main transforming proteins. Studies have suggested that steroid hormones may enhance the expression of these genes leading to loss of p53 gene-mediated cell apoptosis.

Methods

A total of 120 cervical tissue samples were obtained from patients with proven cervical cancer. Patients who used depo-medroxyprogesterone acetate steroid contraception were recruited as part of the study arm. Only HPV DNA type 16 samples were used for the study. Controls included three cell lines (CaSki, SiHa, & C33A) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal housekeeping gene. Of 120 patients, there were 111 patients with HPV type 16 identified. Of this number, RNA was present in 63 samples. There were 30 women (30/63) who used steroid contraception. In relation to patients who used contraception, HPV 16 *E6* gene expression was present in 79% (n = 23) and 88% (n = 30) of steroid users compared to nonusers, respectively. In total there were 25 patients (40%) with expression of the HPV 16 *E6*I* gene and 30 patients with expression of the *E6*II* gene. There were 57% of steroid users (n = 17) who had expression of the *E6*I/E6*II* gene, compared to 52% (n = 17) of nonusers (P = 0.800).

Conclusion

From a molecular level, this study reflects almost similar distribution of the HPV 16 *E6/E6*1* and *E6*11* and does not confirm the role of injectable progestones in cervical carcinogenesis. Further studies with larger patient numbers are needed.

DECLARATION

This study represents work done by the author.

The research described in this thesis was performed in the Department of Obstetrics and Gynaecology, Inkosi Albert Luthuli Central Hospital, Durban, South Africa.

ACKNOWLEDGEMENTS

- 1. Professor BG Lindeque for his unwaivering support and encouragement over the years.**
- 2. Susan Sewart, Department of Biological and Life Sciences, University of Liverpool, Liverpool, United Kingdom, for her technical assistance in the project.**
- 3. Dr I Kleinsmidt and Cathy Connolly, Biostatistics, Medical Research Council, Durban, South Africa**
- 4. The South African Society of Obstetricians and Gynaecologists for their financial support.**
- 5. Mr A Hirasen for his expert drawings**
- 6. Mr H Garbers (MSD South Africa) for granting permission to use the HPV phylogentic tree**
- 7. All patients who contributed to the project.**

PRESENTATION ARISING FROM THE PROJECT

- 1. ACADEMIC MEETING DEPARTMENT OBSTETRICS GYNAECOLOGY 2005**
- 2. THE OBSTETRIC AND GYNAECOLOGY UPDATE, UNIVERSITY OF PRETORIA, MAY 2009.**
- 3. SOUTH AFRICAN SOCIETY OBSTETRICIANS GYNAECOLOGISTS 2010**

PUBLICATIONS ARISING FROM THE STUDY

- 1. An investigation into oral contraceptive use, human papillomavirus (HPV)-type distribution and cervical intraepithelial neoplasia, Durban, South Africa. Eur J Gynaecol Oncol 2009 (accepted for publication).**
- 2. The interaction between steroid hormones, human papillomavirus type 16, E6 oncogene expression and cervical cancer. Int J Gynecol Cancer 2003; 13: 1-9.**
- 3. The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer: a review. Int J Gynecol Cancer 2003; 13: 103-110.**
- 4. Use of the nested reverse transcription-polymerase chain reaction for the detection of human papillomavirus 16 E6 transcriptional activity in cervical cancer: A technical perspective. Eur J Gynecol Oncol 2003; 25: 51 - 54**

TABLE OF CONTENTS

CHAPTER ONE

INTRODUCTION	1
1.0 EPIDEMIOLOGY OF CERVICAL CANCER	2
1.1 RISK FACTORS AND AETIOLOGY OF CERVICAL CANCER AND IT'S PRECURSORS	5
1.1.1 PARITY	5
1.1.2 THE NUMBER OF SEXUAL PARTNERS AND FREQUENCY OF SEXUAL INTERCOURSE	6
1.1.3 SMOKING	6
1.1.4 ROLE OF THE MALE PARTNER	8
1.1.5 ROLE OF DIETARY FACTORS	9
1.1.6 ROLE OF SEXUALLY TRANSMITTED INFECTIONS OTHER THAN HPV	9
1.1.7 ROLE OF THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION	11
2.0 THE HUMAN PAPILLOMAVIRUS AND ITS LINK TO INTRAEPITHELIAL AND INVASIVE CERVICAL NEOPLASIA	16
2.1 HISTORICAL PERPECTIVE	16

2.2	EPIDEMIOLOGICAL EVIDENCE LINKING HPV AND CERVICAL NEOPLASIA	17
2.3	CLASSIFICATION AND STRUCTURE OF PAPILLOMAVIRUSES	20
2.4	STRUCTURE OF THE HUMAN PAPILLOMAVIRUS	22
2.5	THE HPV NUCLEIC ACID/GENOME	22
	2.5.1 ORFs WITH ONCOGENIC PROPERTIES	24
	2.5.2 REGULATORY GENES	37
	2.5.3 UNKNOWN GENE FUNCTIONS	37
	2.5.4 LATE CAPSID PROTEINS AND THE UPSTREAM REGULATORY REGION	39
2.6	REPLICATION CYCLE OF THE HUMAN PAPILLOMAVIRUS	40
2.7	IMMUNOLOGY OF HPV INFECTIONS	41

3.0	CLINICAL CORRELATES OF HPV TYPES	45
3.1	CUTANEOUS HPV_s IN IMMUNO-COMPETANT POPULATION	45
3.2	CUTANEOUS HPV_s IN IMMUNO-COMPROMISED INDIVIDUALS	46
3.3	HPV_s AFFECTING THE AERO-DIGESTIVE AND ANOGENITAL MUCOSAE	47
	3.3.1 LOW-RISK HPV TYPES	47
	3.3.2 HIGH-RISK HUMAN PAPILOMAVIRUSES	48
	3.3.2.1 HPV TYPE 16 VIRUS	48
	3.3.2.2 HPV TYPE 18 VIRUS	49
4.0	VULNERABILITY OF THE HOST TO CERVICAL NEOPLASIA	50
4.1	THE CELL CYCLE AND ITS ASSOCIATION WITH HUMAN PAPILOMAVIRUS INFECTION	52
4.2	CELL-CYCLE PROTEINS	53
	4.2.1 CYCKLIN-DEPENDENT KINASES	53
	4.2.2 CYCLINS	54



4.2.3	CYCLIN-DEPENDENT KINASE INHIBITORS	54
4.2.4	CYCLE-CYCLE PHASES	55
4.2.4.1	G1/S PHASE	55
4.2.4.2	G2/M PHASE	55
4.2.4.3	CELL-CYCLE CHECKPOINTS	56
5.0	THE ROLE OF HPV IN RELATION TO THE CELL CYCLE	57
6.0	THE <i>p53</i> GENE AND ITS ROLE IN CERVICAL CANCER	59
6.1	HISTORY	59
6.2	THE <i>p53</i> GENE AND CERVICAL CANCER	62
7.0	THE ROLE OF TELOMERASE ACTIVITY IN HPV-RELATED CERVICAL CANCER	64
8.0	THE ROLE OF DNA METHYLATION IN CERVICAL CANCER	65
9.0	MICROSTAELLITE INSTABILITY AND CERVICAL CANCER	66
10.0	THE ROLE OF STEROID CONTRACEPTION, HUMAN PAPILLOMAVIRUS AND CERVICAL NEOPLASIA	69

10.1	INTRODUCTION	69
10.2	THE BENEFITS OF STEROID CONTRACEPTION	70
10.3	CANCERS LINKED TO STEROID CONTRACEPTION	71
10.4	REVIEW OF PUBLISHED DATA LINKING STEROID CONTRACEPTION TO CERVICAL NEOPLASIA	72
	10.4.1 EVIDENCE FROM COHORT STUDIES	72
	10.4.2 EVIDENCE FROM CASE-CONTROLLED STUDIES	76
10.5	ROLE OF PROGESTERONE-ONLY CONTRACEPTIVE AGENTS IN THE PATHOGENESIS OF CERVICAL NEOPLASIA	82
11.0	POSTULATED MECHANISMS OF STEROID-RELATED CERVICAL CARCINOGENESIS AND THE LINK BETWEEN STEROID CONTRACEPTION AND HUMAN PAPILLOMAVIRUS INFECTION	86
12.0	THE IMPLICATIONS OF THE EVIDENCE PROVIDED FOR CLINICAL PRACTICE WITH REGARDS TO STEROID CONTRACEPTION	93
13.0	HPV VACCINES AND THE FUTURE	94

14.0 PART ONE OF THE PROJECT 99

**AN INVESTIGATION INTO ORAL CONTRACEPTIVE USAGE, HUMAN
PAPILLOMAVIRUS (HPV)-TYPE DISTRIBUTION AND CERVICAL
INTRAEPITHELIAL NEOPLASIA, DURBAN, SOUTH AFRICA**

14.1 AIMS 99

14.2 PATIENTS AND METHODS 99

14.3 STATISTICAL METHODS 101

14.4 RESULTS 102

14.5 DISCUSSION 110

15.0 PART TWO OF THE PROJECT 115

**AN INVESTIGATION INTO HPV 16 E6 ONCOGENE- EXPRESSION
AND USE OF INJECTABLE MEDROXY-PROGESTERONE STEROID
CONTRACEPTIVES AMONG WOMEN WITH INVASIVE CERVICAL
CANCER**

15.1	HYPOTHESIS OF THE STUDY	114
15.2	AIMS	116
15.3	MATERIALS AND METHODS	116
15.4	LABORATORY METHODS	118
15.4.1	TYPING OF THE CERVICAL TISSUE SPECIMENS FOR HPV 16	
15.4.1.1	DNA EXTRACTION	120
15.4.1.2	HPV TYPING	121
15.4.2	GROWTH OF CELL LINES <i>IN VITRO</i>	124
15.4.3	EXTRACTION OF RIBONUCLEIC ACID (RNA) FROM TISSUE SPECIMENS;	126
15.4.4	ASSESSMENT OF THE QUALITY AND QUANTITY OF RNA EXTRACTED BY SPECTROPHOTOMETRY;	127
15.4.5	REVERSE TRANSCRIPTION OF RNA TO SYNTHESISE cDNA USING REVERSE TRANSCRIPTASE ENZYME;	129
15.4.6	MOCK REVERSE TRANSCRIPTION OF RNA WITHOUT REVERSE TRANSCRIPTASE ENZYME TO DIFFERENTIATE RNA FROM GENOMIC DEOXYRIBONUCLEIC ACID (DNA);	130

15.4.7	POLYMERASE CHAIN REACTION OF PRODUCTS FROM 16.5) AND 16.6) ABOVE USING SPECIFIC PRIMER PAIRS TO THE <i>E6</i> ONCOGENE;	131
15.4.8	NESTED POLYMERASE CHAIN REACTION OF PRODUCTS FROM 16.7) ABOVE USING SPECIFIC PRIMER PAIRS TO DETERMINE THE EXPRESSION OF HPV 16 <i>E6*I</i> AND <i>E6*II</i> SPLICED VARIANTS;	136
15.4.9	GEL ELECTROPHORESIS TO DETERMINE THE EXPRESSION OF THE <i>E6</i>, <i>E6*I</i> AND <i>E6*II</i> ONCOGENES IN BOTH GROUPS OF PATIENTS;	137
15.4.10	COMPARISON OF THE PRESENCE OR ABSENCE OF BANDS WITH THE USE OF THE S3/S4 PRIMERS AND S1/S2 PRIMERS IN RELATION TO THE USAGE OF STEROID CONTRACEPTION	138
16.0	STATISTICAL METHODS	138

17.0	RESULTS	139
17.1	PATIENT DEMOGRAPHICS	139
17.2	CLINICAL DATA	139
17.3	CONTRACEPTIVE DATA	140
17.4	SMOKING	141
17.5	RNA EXTRACTION	141
17.6	HISTOLOGY FOR 63 PATIENTS	143
17.7	CLINICAL STAGES FOR 63 PATIENTS	145
17.8	EXPRESSION OF HPV 16 <i>E6</i>, <i>E6*I</i> & <i>E6*II</i> ONCOGENES FOR 63 PATIENTS	148
17.9	CLINICAL STAGE VERSUS HPV 16 <i>E6</i> ONCOGENE EXPRESSION	150
17.10	EXPRESSION OF THE HPV TYPE 16 <i>E6*I/E6*II</i> ONCOGENES IN STEROID USERS AND NON-STEROID USERS	150
17.11	EXPRESSION OF THE HPV 16 <i>E6*I/E6*II</i> IN RELATION TO STAGE	150
18.0	DISCUSSION	155



19.0	CHAPTER FIVE	166	
	19.1	CONCLUSIONS AND RECOMMENDATIONS	166
20.0	APPENDIX	168	
21.0	REFERENCES	180	